ImCheck Therapeutics is designing and developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules and engage a specific type of immune cells, γ9δ2 T cells.
ImCheck has developed a broad pipeline of monoclonal antibody (mAB) drug candidates targeting BTNs with its lead program entering clinical evaluation in 2020. Due to their mechanism of action, including the ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class" mAbs may be able to improve upon the first-generation of checkpoint inhibitors in cancer. ImCheck’s programs also have potential in autoimmune indications, which the company is currently investigating.
Starting in 2020, the company's first drug candidate, an anti-BTN3 antibody, is expected to begin phase I assessment in oncology.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a world-renowed researcher in γδT cells and butyrophilins, from the experience of an expert management team and from the commitment of leading life science-focused investors.